PLRX - PLIANT THERAPEUTICS, INC.

QQQ $ 425.65 $ 0.41 (0.1 %)

DIA $ 381.56 $ 0.04 (0.01 %)

SPY $ 503.86 $ -0.54 (-0.11 %)

TLT $ 88.96 $ 0.74 (0.84 %)

GLD $ 213.58 $ 1.12 (0.53 %)

Previous Close

$ 12.66

Open

$ 13.02

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 12.70 - $ 13.07

52 Week Range

$ 11.21 - $ 24.74

Volume

691,014

Average Volume

Market Cap

743.38M

Beta (5Y Monthly)

$ 1.02

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-27-2024	12-31-2023	10-K
2	11-09-2023	09-30-2023	10-Q
3	08-09-2023	06-30-2023	10-Q
4	05-09-2023	03-31-2023	10-Q
5	03-09-2023	12-31-2022	10-K
6	11-08-2022	09-30-2022	10-Q
7	08-08-2022	06-30-2022	10-Q
8	05-09-2022	03-31-2022	10-Q
9	02-28-2022	12-31-2021	10-K
10	11-09-2021	09-30-2021	10-Q
11	08-09-2021	06-30-2021	10-Q
12	05-10-2021	03-31-2021	10-Q
13	03-16-2021	12-31-2020	10-K
14	11-10-2020	09-30-2020	10-Q
15	08-11-2020	06-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Needham Reiterates Buy on Pliant Therapeut...
04/10/2024 10:45:03

Needham analyst Joseph Stringer reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.

Needham Reiterates Buy on Pliant Therapeut...
03/12/2024 16:40:00

Needham analyst Joseph Stringer reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.

Pliant Therapeutics Announces Accelerated ...
03/12/2024 11:35:28

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of ...

RBC Capital Maintains Outperform on Pliant...
03/05/2024 15:32:41

RBC Capital analyst Brian Abrahams maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and raises the price target...

HC Wainwright & Co. Reiterates Buy on Plia...
02/28/2024 17:52:24

HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $48 price target.

RBC Capital Maintains Outperform on Pliant...
02/28/2024 15:27:49

RBC Capital analyst Brian Abrahams maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and lowers the price target...

Needham Reiterates Buy on Pliant Therapeut...
02/28/2024 10:28:36

Needham analyst Joseph Stringer reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.

Pliant Therapeutics Q4 2023 GAAP EPS $(0.6...
02/27/2024 22:18:35

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $...

Needham Maintains Buy on Pliant Therapeuti...
02/05/2024 18:54:38

Needham analyst Joseph Stringer maintains Pliant Therapeutics (NASDAQ:PLRX) with a Buy and lowers the price target from $45 ...

why-air-products-and-chemicals-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Air Products and Chemicals Shares Are ...
02/05/2024 17:56:50

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-th...

why-is-liver-disease-focused-pliant-therapeutics-stock-trading-lower-today

Why Is Liver Disease-Focused Pliant Therap...
02/05/2024 17:26:27

Pliant Therapeutics reports 12-week interim data for bexotegrast in INTEGRIS-PSC Phase 2a trial. 320 mg group met primary and s...

HC Wainwright & Co. Maintains Buy Rating f...
02/05/2024 17:00:09

HC Wainwright & Co. Maintains Buy on Plian...
02/05/2024 11:36:02

HC Wainwright & Co. analyst Ed Arce maintains Pliant Therapeutics (NASDAQ:PLRX) with a Buy and lowers the price target f...

Pliant Therapeutics Announced Bexotegrast ...
02/04/2024 20:42:31

Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a mult...

The Latest Analyst Ratings for Pliant Ther...
11/10/2023 21:00:25

RBC Capital Maintains Outperform on Pliant...
11/10/2023 19:24:16

RBC Capital analyst Brian Abrahams maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and lowers the price target...

Pliant Therapeutics Q3 EPS $(0.70) Beats $...
11/09/2023 22:24:32

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $...

Pliant Therapeutics Presentations At The A...
11/06/2023 13:52:29

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of ...

Pliant Therapeutics Announces Three Presen...
10/31/2023 20:42:57

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of ...

Pliant Therapeutics INTEGRIS-PSC Phase 2a ...
10/19/2023 12:22:01

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of ...